SUBSCRIBE
SUBSCRIBE

Elicio Therapeutics

IN THE PRESS
Business
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 13, 2024
 · 
12 min read
Press Releases
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
August 13, 2024
 · 
5 min read
Genetown
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
May 23, 2024
 · 
9 min read
Business
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 15, 2024
 · 
11 min read
Genetown
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
April 25, 2024
 · 
5 min read
Genetown
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
April 5, 2024
 · 
13 min read
Business
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
March 29, 2024
 · 
10 min read
Deals
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
March 18, 2024
 · 
4 min read
Genetown
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
March 6, 2024
 · 
8 min read
Genetown
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 5, 2024
 · 
1 min read
Load More
JOBS